Overview

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury

Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to investigate the safety and tolerability of repeat dosing with zampilimab in kidney transplant recipients with deteriorating kidney function associated with chronic allograft injury (CAI).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
UCB Biopharma SRL